PE20231680A1 - Anticuerpos anti-cd30l y usos de estos - Google Patents
Anticuerpos anti-cd30l y usos de estosInfo
- Publication number
- PE20231680A1 PE20231680A1 PE2023002377A PE2023002377A PE20231680A1 PE 20231680 A1 PE20231680 A1 PE 20231680A1 PE 2023002377 A PE2023002377 A PE 2023002377A PE 2023002377 A PE2023002377 A PE 2023002377A PE 20231680 A1 PE20231680 A1 PE 20231680A1
- Authority
- PE
- Peru
- Prior art keywords
- cdr
- seq
- nos
- cd30l
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
El presente documento da a conocer anticuerpos que se unen al ligando de CD30 (CD30L, CD153, TNFSF8) y son utiles en el tratamiento de trastornos autoinmunitarios tales como la IBD (enteropatia inflamatoria). Estos anticuerpos inhiben la interaccion entre CD30L y CD30 para reducir, inhibir o prevenir con eficacia la activacion inmunitaria (por ejemplo, una respuesta inflamatoria). Tambien se refiere a un anticuerpo o fragmento de union a antigeno de este que se une a CD30L, en donde el anticuerpo o fragmento de union a antigeno de este comprende: (a) una CDR-H1 que comprende cualquiera de las SEQ ID NO: 100 a 139, 220 a 234, 465 a 489, 628 a 641, y 712 a 723; 10 (b) una CDR-H2 que comprende cualquiera de las SEQ ID NO: 140 a 179, 235 a 249, 490 a 499, 513 a 527, 642 a 655 y 724 a 735; (c) una CDR-H3 que comprenden cualquiera de las SEQ ID NO: 180 a 219, 250 a 264, 528 a 552, 656 a 669, y 736 a 743; (d) una CDR-L1 que comprende cualquiera de las 15 SEQ ID NO: 300 a 339, 420 a 434, 553 a 577, 670 a 683, y 744 a 751; (d) CDR-L2 que comprende cualquiera de las SEQ ID NO: 340 a 379, 435 a 449, 578 a 602, 684 a 697 y 752 a 759; y/o (e) una CDR-L3 que comprende cualquiera de las SEQ ID NO: 380 a 419, 450 a 464, 603 a 627, 698 a 711 y 760 a 765.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163150373P | 2021-02-17 | 2021-02-17 | |
| PCT/US2022/016565 WO2022177963A1 (en) | 2021-02-17 | 2022-02-16 | Anti-cd30l antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231680A1 true PE20231680A1 (es) | 2023-10-19 |
Family
ID=82931610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023002377A PE20231680A1 (es) | 2021-02-17 | 2022-02-16 | Anticuerpos anti-cd30l y usos de estos |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20240254246A1 (es) |
| EP (1) | EP4294840A4 (es) |
| JP (2) | JP7559257B2 (es) |
| KR (1) | KR20230157356A (es) |
| CN (2) | CN117255802A (es) |
| AR (1) | AR124895A1 (es) |
| AU (1) | AU2022224561A1 (es) |
| BR (1) | BR112023016445A2 (es) |
| CA (1) | CA3208060A1 (es) |
| CL (1) | CL2023002393A1 (es) |
| CO (1) | CO2023011962A2 (es) |
| CR (1) | CR20230445A (es) |
| EC (1) | ECSP23070234A (es) |
| GE (1) | GEP20257791B (es) |
| IL (1) | IL305146A (es) |
| MX (1) | MX2023009621A (es) |
| PE (1) | PE20231680A1 (es) |
| TW (1) | TW202302637A (es) |
| WO (1) | WO2022177963A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021133822A1 (en) | 2019-12-24 | 2021-07-01 | Juvena Therapeutics,Inc. | Regenerative polypeptides and uses thereof |
| CN117255802A (zh) * | 2021-02-17 | 2023-12-19 | 普罗米修斯生物科学公司 | 抗cd30l抗体和其用途 |
| EP4359425A4 (en) | 2021-06-21 | 2025-04-09 | Juvena Therapeutics, Inc. | REGENERATIVE POLYPEPTIDES AND THEIR USES |
| EP4562050A1 (en) * | 2022-07-25 | 2025-06-04 | Prometheus Biosciences, Inc. | Anti-cd30l antibodies, formulations therefor, and uses thereof |
| WO2024143497A1 (ja) * | 2022-12-28 | 2024-07-04 | 国立大学法人京都大学 | Ｃｄ１５３を標的とする医薬組成物 |
| AR133766A1 (es) * | 2023-09-12 | 2025-10-29 | Amgen Inc | Anticuerpos anti-cd30l y usos de los mismos |
| WO2025075049A1 (ja) * | 2023-10-03 | 2025-04-10 | 国立大学法人京都大学 | ヒトｃｄ１５３を標的とする抗体ならびにキメラ抗原受容体 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1993024135A1 (en) * | 1992-05-26 | 1993-12-09 | Immunex Corporation | Novel cytokine that binds cd30 |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| US6652854B2 (en) * | 2000-08-08 | 2003-11-25 | Immunex Corporation | Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| CA2536086C (en) | 2003-08-20 | 2013-03-19 | University Of Miami | Inhibition of dr3 in the treatment of allergic lung inflammation |
| SG11201401536QA (en) * | 2011-10-21 | 2014-05-29 | Nestec Sa | Methods for improving inflammatory bowel disease diagnosis |
| PT2841456T (pt) * | 2012-04-27 | 2018-10-19 | Novo Nordisk As | Proteinas de ligação ao antigénio do ligando de cd30 humano |
| US10358497B2 (en) * | 2015-09-29 | 2019-07-23 | Amgen Inc. | Methods of treating cardiovascular disease with an ASGR inhibitor |
| US20210208162A1 (en) | 2016-01-19 | 2021-07-08 | Global Down Syndrome Foundation | Down syndrome biomarkers and uses thereof |
| RS64747B1 (sr) * | 2018-04-30 | 2023-11-30 | Cedars Sinai Medical Center | Postupci i sistemi za odabir i lečenje pacijenata sa inflamatornim bolestima |
| WO2020096046A1 (ja) | 2018-11-09 | 2020-05-14 | 国立大学法人大阪大学 | 老化関連ｔ細胞を標的とした糖代謝異常の予防または治療用ワクチン |
| CN117255802A (zh) * | 2021-02-17 | 2023-12-19 | 普罗米修斯生物科学公司 | 抗cd30l抗体和其用途 |
-
2022
- 2022-02-16 CN CN202280028982.8A patent/CN117255802A/zh active Pending
- 2022-02-16 CA CA3208060A patent/CA3208060A1/en active Pending
- 2022-02-16 KR KR1020237031681A patent/KR20230157356A/ko active Pending
- 2022-02-16 IL IL305146A patent/IL305146A/en unknown
- 2022-02-16 AR ARP220100318A patent/AR124895A1/es unknown
- 2022-02-16 EP EP22756817.7A patent/EP4294840A4/en active Pending
- 2022-02-16 MX MX2023009621A patent/MX2023009621A/es unknown
- 2022-02-16 BR BR112023016445A patent/BR112023016445A2/pt unknown
- 2022-02-16 AU AU2022224561A patent/AU2022224561A1/en active Pending
- 2022-02-16 CR CR20230445A patent/CR20230445A/es unknown
- 2022-02-16 JP JP2023549602A patent/JP7559257B2/ja active Active
- 2022-02-16 WO PCT/US2022/016565 patent/WO2022177963A1/en not_active Ceased
- 2022-02-16 TW TW111105667A patent/TW202302637A/zh unknown
- 2022-02-16 CN CN202410189800.6A patent/CN118047872A/zh active Pending
- 2022-02-16 US US18/546,955 patent/US20240254246A1/en active Pending
- 2022-02-16 PE PE2023002377A patent/PE20231680A1/es unknown
- 2022-02-16 GE GEAP202216351A patent/GEP20257791B/en unknown
- 2022-08-26 US US17/822,598 patent/US11866505B2/en active Active
-
2023
- 2023-08-14 CL CL2023002393A patent/CL2023002393A1/es unknown
- 2023-09-08 CO CONC2023/0011962A patent/CO2023011962A2/es unknown
- 2023-09-14 EC ECSENADI202370234A patent/ECSP23070234A/es unknown
- 2023-11-15 US US18/510,511 patent/US20240092923A1/en active Pending
-
2024
- 2024-09-17 JP JP2024160401A patent/JP2025004013A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118047872A (zh) | 2024-05-17 |
| CO2023011962A2 (es) | 2023-09-29 |
| EP4294840A1 (en) | 2023-12-27 |
| US20230060624A1 (en) | 2023-03-02 |
| GEP20257791B (en) | 2025-09-10 |
| WO2022177963A1 (en) | 2022-08-25 |
| AU2022224561A9 (en) | 2023-10-05 |
| TW202302637A (zh) | 2023-01-16 |
| KR20230157356A (ko) | 2023-11-16 |
| AU2022224561A1 (en) | 2023-09-28 |
| MX2023009621A (es) | 2023-10-31 |
| BR112023016445A2 (pt) | 2023-12-12 |
| EP4294840A4 (en) | 2025-06-11 |
| JP2024509746A (ja) | 2024-03-05 |
| CN117255802A (zh) | 2023-12-19 |
| JP7559257B2 (ja) | 2024-10-01 |
| CL2023002393A1 (es) | 2024-03-22 |
| AR124895A1 (es) | 2023-05-17 |
| JP2025004013A (ja) | 2025-01-14 |
| US11866505B2 (en) | 2024-01-09 |
| ECSP23070234A (es) | 2023-10-31 |
| IL305146A (en) | 2023-10-01 |
| US20240254246A1 (en) | 2024-08-01 |
| US20240092923A1 (en) | 2024-03-21 |
| CA3208060A1 (en) | 2022-08-25 |
| CR20230445A (es) | 2023-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20231680A1 (es) | Anticuerpos anti-cd30l y usos de estos | |
| PE20200862A1 (es) | Anticuerpos anti-trem2 y metodos relacionados | |
| PE20181089A1 (es) | Anticuerpos anti-cd19 humano con alta afinidad | |
| RU2012147286A (ru) | Гуманизированные антитела к фактору d и их применения | |
| PE20211605A1 (es) | ANTICUERPOS ANTI-avß8 Y COMPOSICIONES Y USOS DE LOS MISMOS | |
| PE20211709A1 (es) | Anticuerpos que reconocen tau | |
| JP2020037555A5 (es) | ||
| RU2017137010A (ru) | Анти-сеасам6 антитела и их применения | |
| JP2018510636A5 (es) | ||
| MX2018014714A (es) | Composiciones para inhibir la activacion del complemento dependiente de la masp-2. | |
| PE20141186A1 (es) | Proteinas de union al tnf-alfa | |
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| RU2008129111A (ru) | Антитела к ox40l и способы их применения | |
| PE20231504A1 (es) | Anticuerpos especificos para kras y sus usos | |
| UA108466C2 (en) | Antibody antagonises c-Met | |
| AR078796A1 (es) | Composiciones y metodos para tratar trastornos inflamatorios | |
| PE20251278A1 (es) | Anticuerpos anti-tl1a y metodos de uso de los mismos | |
| RU2022108410A (ru) | Терапевтические антитела против лиганда cd40 | |
| AR115192A1 (es) | Anticuerpos | |
| JP2021509012A5 (es) | ||
| PE20230844A1 (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicacion de los mismos | |
| PE20221511A1 (es) | Anticuerpos anti-ly6g6d y metodos de uso | |
| FI3452515T3 (fi) | HER-2 sitoutuvia vasta-aineita | |
| PE20231953A1 (es) | Anticuerpos multiespecificos y combinaciones de anticuerpos | |
| PE20250390A1 (es) | Anticuerpos anti-c3 y fragmentos de union al antigeno de estos y sus usos para tratar enfermedades oftalmicas u oculares |